Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Department of Otorhinolaryngology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Mod Rheumatol Case Rep. 2021 Jul;5(2):327-332. doi: 10.1080/24725625.2021.1881205. Epub 2021 Feb 18.
Recently, mepolizumab, an interleukin (IL)-5 inhibitor, has been indicated for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) refractory to standard therapies. However, no reports have compared the efficacy of mepolizumab according to symptoms and organ lesions. Herein, we report two cases in which mepolizumab was highly effective in the management of EGPA with lung lesions and otitis media refractory to treatment with multiple immunosuppressive agents. These two cases suggest that mepolizumab is effective in treating pulmonary and ear lesions in EGPA.
最近，白细胞介素 (IL)-5 抑制剂美泊利珠单抗已被批准用于治疗对标准治疗方案无反应的嗜酸性肉芽肿性多血管炎（EGPA）。然而，目前尚无研究比较美泊利珠单抗针对不同症状和器官病变的疗效。本研究报告了两例接受多种免疫抑制剂治疗后肺部病变和中耳炎仍未缓解的 EGPA 患者，使用美泊利珠单抗治疗后取得了良好的效果。这两例病例提示美泊利珠单抗治疗 EGPA 的肺部和耳部病变可能有效。
